Fractionated radiation therapy in combination with adenoviral delivery of the cytosine deaminase gene and 5-fluorocytosine enhances cytotoxic and antitumor effects in human colorectal and cholangiocarcinoma models

Gene Therapy

Volumn 7, Issue 12, 2000, Pages 1019-1026

  Stackhouse, M A ^a   Pederson, L C ^b   Grizzle, W E ^c   Curiel, D T ^d   Gebert, J ^e   Haack, K ^e   Vickers, S M ^b   Mayo, M S ^f   Buchsbaum, D J ^a  

^a The University of Alabama at Birmingham   (United States)

^b Kentucky   (United States)

^c University of Alabama at Birmingham   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^e UNIVERSITY OF HEIDELBERG   (Germany)

^f UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

Author keywords

Cholangiocarcinoma; Colon cancer; Cytosine deaminase; Gene therapy; Molecular chemotherapy; Radiation therapy

Indexed keywords

CYTOSINE DEAMINASE; FLUCYTOSINE;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BILE DUCT CARCINOMA; CANCER CELL CULTURE; COLON CARCINOMA; CONTROLLED STUDY; CYTOMEGALOVIRUS; DRUG CYTOTOXICITY; GENE TARGETING; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR XENOGRAFT;

ADENOVIRIDAE; ANIMALIA; BACTERIA (MICROORGANISMS); CYTOMEGALOVIRUS;

EID: 0034086627     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3301196     Document Type: Article

References (25)

1. Lawrence TS, Tepper JE. Combined radiation therapy and chemotherapy - 5-FU and FUdR. Semin Radiat Oncol 1997; 7: 247-334.
2. Hsue V et al. A phase I study of combined radiation therapy with 5-fluorouracil and low dose folinic acid in patients with locally advanced pancreatic or biliary carcinoma. Int J Radiat Oncol Biol Phys 1996; 34: 445-450.
3. Oberfield RA, Rossi RL. The role of chemotherapy in the treatment of bile duct cancer. World J Surg 1988; 12: 105-108.
4. Buchsbaum DJ et al. Approaches to enhance cancer radiotherapy employing gene transfer methods. Gene Therapy 1996; 3: 1042-1068.
5. Weichselbaum RR et al. Gene therapy targeted by radiation preferentially radiosensitizes tumor cells. Cancer Res 1994; 54: 4266-4269.
6. Kim JH, Kim SH, Brown SL, Freytag SO. Selective enhancement by an antiviral agent of the radiation-induced cell killing of human glioma cells transduced with HSV-tk gene. Cancer Res 1994; 54: 6053-6056.
7. Khil MS et al. Radiosensitization by 5-fluorocytosine of human colorectal carcinoma cells in culture transduced with cytosine deaminease gene. Clin Cancer Res 1996; 2: 53-57.
8. Pederson LC et al. Molecular chemotherapy combined with radiation therapy enhances killing of cholangiocarcinoma cells in vitro and in vivo. Cancer Res 1997; 57: 4325-4332.
9. Spitz FR et al. Adenoviral-mediated wild-type p53 gene expression sensitizes colorectal cancer cells to ionizing radiation. Clin Cancer Res 1996; 2: 1665-1671.
10. Huber BE et al. In vivo antitumor activity of 5-fluorocytosine on human colorectal carcinoma cells genetically modified to express cytosine deaminase. Cancer Res 1993; 53: 4619-4626.
11. Pederson LC et al. Combining cytosine deaminase expression, 5-fluorocytosine exposure, and radiotherapy increases cytotoxicity to cholangiocarcinoma cells. J Gastrointest Surg 1998; 2: 283-291.
12. Rogulski KR, Kim JH, Kim SH, Freytag SO. Glioma cells transduced with an Escherichia coli CD/HSV-1 TK fusion gene exhibit enhanced metabolic suicide and radiosensitivity. Hum Gene Ther 1997; 8: 73-85.
13. Dong Y et al. In vivo replication-deficient adenovirus vector-mediated transduction of the cytosine deaminase gene sensitizes glioma cells to 5-fluorocytosine. Hum Gene Ther 1996; 7: 713-720.
14. Hirschowitz EA et al. In vivo adenovirus-mediated gene transfer of the Escherichia coli cytosine deaminase gene to human colon carcinoma-derived tumors induces chemosensitivity to 5-fluorocytosine. Hum Gene Ther 1995; 6: 1055-1063.
15. Ohwada A, Hirschowitz EA, Crystal RG. Regional delivery of an adenovirus vector containing the Escherichia coli cytosine deaminase gene to provide local activation of 5-fluorocytosine to suppress the growth of colon carcinoma metastatic to liver. Hum Gene Ther 1996; 7: 1567-1576.
16. Saunders K et al. Diffuse bile duct tumors: guidelines for management. Am Surg 1991; 57: 816-820.
17. Vauthey J-N, Blumgart LH. Recent advances in the management of cholangiocarcinomas. Semin Liver Dis 1994; 14: 109-114.
18. Denning C, Pitts JD. Bystander effects of different enzyme-prodrug systems for cancer gene therapy depend on different pathways for intercellular transfer of toxic metabolites, a factor that will govern clinical choice of appropriate regimes. Hum Gene Ther 1997; 8: 1825-1835.
19. Paillard F. Bystander effects in enzyme/prodrug gene therapy. Hum Gene Ther 1997; 8: 1733-1736.
20. Becker TC et al. Use of recombinant adenovirus for metabolic engineering of mammalian cells. Meth Cell Biol 1994; 43: 161-189.
21. Grizzle WE, Myers RB, Manne U, Srivastava S. Immunohistochemical evaluation of biomarkers in prostatic and colorectal neoplasia. In: Hanausek M, Walaszek Z (eds). John Walker's Methods in Molecular Medicine - Tumor Marker Protocols. Humana Press: Totowa, NJ, 1998, pp 143-160.
22. Grizzle WE et al. Factors affecting immunohistochemical evaluation of biomarker expression in neoplasia. In: Hanausek M, Walaszek Z (eds). John Walker's Methods in Molecular Medicine - Tumor Marker Protocols. Humana Press: Totowa, 1998, pp 161-179.
23. Manne U et al. Prognostic significance of Bcl-2 expression and p53 nuclear accumulation in colorectal adenocarcinoma. Int J Cancer 1997; 74: 346-358.
24. Myers RB, Grizzle WE. Biomarker expression in prostatic intraepithelial neoplasia. Eur Urol 1996; 30: 153-166.
25. Haack K et al. Detection of cytosine deaminase in genetically modified tumor cells by specific antibodies. Hum Gene Ther 1997; 8: 1395-1401.